Fig. 4: Onset and persistence of PrEP efficacy. | Nature Communications

Fig. 4: Onset and persistence of PrEP efficacy.

From: Pharmacological markers of HIV prevention for oral pre-exposure prophylaxis in men who have sex with men

Fig. 4: Onset and persistence of PrEP efficacy.The alternative text for this image may have been generated using AI.

a Onset of PrEP efficacy after initiation of daily oral TDF/FTC-based PrEP (dosing scheme indicated by blue 'pill' symbol) and persistence of HIV protection after stopping PrEP intake. b Onset of PrEP efficacy after 2-1-1 TDF/FTC-based PrEP on demand and duration of HIV protection after the last dose. Thick blue lines indicate the median PrEP efficacy and shaded areas correspond to 95% confidence intervals considering pharmacokinetic variability. Simulations were conducted assuming that FTC-TP and TFV-DP concentrations in PBMC predict prophylactic efficacy. Δ t = (time of virus exposure - time of first dose). Source data are provided as a Source Data file. TDF: tenofovir disoproxil fumarate, FTC: emtricitabine, PrEP: pre-exposure prophylaxis, FTC-TP: emtricitabine triphosphate, TFV-DP: tenofovir diphosphate, PEP: post-exposure prophylaxis, PBMC: peripheral blood mononuclear cells.

Back to article page